

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 31665

Title: ECRG2 enhances the anticancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via up-regulation of p53 and down-regulation of PCNA

Reviewer's code: 02458675

Reviewer's country: Italy

Science editor: Yuan Qi

Date sent for review: 2016-12-02 11:09

Date reviewed: 2016-12-15 12:04

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This is an interesting study about the ECRG2 enhances the anticancer effects of cisplatin in cisplatin-resistant esophageal cancer cells. In this study, Hou et al explored the anti-tumor effects of ECRG2 in combination with cisplatin (DDP) in DDP-resistant esophageal cancer cells. The authors found that ECRG2 in combination with DDP can inhibit viability and induce apoptosis in esophageal cancer cisplatin-resistant cells, possibly through up-regulation of p53 expression and down-regulation of PCNA expression. These findings suggested the combination of ECRG2 and cisplatin may be a promising strategy for clinical treatment of esophageal cancers that are resistant to cisplatin. The study is well designed and the manuscript is well written. After some minor revisions, it can be accepted for publication in the journal. 1 The manuscript need some minor language editing. 2 Results are interesting and well discussed. 3 The figures are not so clear for print, such as fig 4. And for fig 5, it need an editing, the images are mixed up. 4 The references need to be updated.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 31665

Title: ECRG2 enhances the anticancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via up-regulation of p53 and down-regulation of PNCA

Reviewer's code: 02857975

Reviewer's country: Japan

Science editor: Yuan Qi

Date sent for review: 2016-12-02 11:09

Date reviewed: 2016-12-16 12:16

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Excellent study. After some minor revision of the language, it can be published in the journal.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 31665

Title: ECRG2 enhances the anticancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via up-regulation of p53 and down-regulation of PNCA

Reviewer's code: 03027328

Reviewer's country: United States

Science editor: Yuan Qi

Date sent for review: 2016-12-02 11:09

Date reviewed: 2016-12-16 16:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Accept. No comments.